azomycin has been researched along with Extensively Drug-Resistant Tuberculosis in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.49) | 29.6817 |
| 2010's | 51 (76.12) | 24.3611 |
| 2020's | 15 (22.39) | 2.80 |
| Authors | Studies |
|---|---|
| Avaliani, Z; Conradie, F; Cook-Scalise, S; Everitt, D; Garfin, AMC; Gomez, GB; Juneja, S; Kiria, N; Lomtadze, N; Malhotra, S; Ndjeka, N; Siapka, M; Spigelman, M; Vassall, A | 1 |
| Howell, P; Mvuna, N; Olugbosi, M; Upton, C | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Cook-Scalise, S; Edo, P; Gebhard, A; Juneja, S; Kadyrov, A; Lawanson, A; Malhotra, S; Mambetova, E; Mulder, C; Pambudi, I; Rupert, S; Setiawan, E; Sohn, H; Sugiharto, J; Useni, S; van den Hof, S | 1 |
| Antony, S; Bodhanwala, M; Jaiswal, A; Parmar, M; Sachdeva, KS; Salve, J; Shah, D; Shah, I; Tipre, P | 1 |
| Andersen, ÅB; Dahl, VN; Guglielmetti, L; Holmgaard, FB; Lillebaek, T; Wejse, C | 1 |
| Everitt, D; Nedelman, JR; Salinger, DH; Subramoney, V | 1 |
| Gandhi, S; Shah, I; Shetty, NS | 1 |
| Bateson, A; Conradie, F; Crook, AM; Diacon, AH; Egizi, E; Everitt, D; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Moreira, J; Ngubane, N; Olugbosi, M; Spigelman, M; Timm, J; Van Niekerk, C; Wills, GH | 1 |
| Chander, J; Kaur, M; Mohan, N; Saini, V; Singhal, L | 1 |
| Auchynka, V; Charnysh, I; Hurevich, H; Katovich, D; Klimuk, D; Kumar, AMV; Sereda, Y; Setkina, S; Skrahin, A; Skrahina, A; Solodovnikova, V; Yedilbayev, A | 1 |
| Auchynka, V; Hurevich, H; Katovich, D; Kumar, AMV; Sereda, Y; Setkina, S; Skrahin, A; Skrahina, A; Solodovnikova, V; Yedilbayev, A | 1 |
| Acharya, S; Chavan, V; Das, M; Dhakulkar, S; Ferlazzo, G; Isaakidis, P; Iyer, A; Kalon, S; Mansoor, H; Meneguim, AC; Oswal, V; Ravi, S; Rebello, L; Shah, D; Sutar, N; Thakur, HP; Vengurlekar, D | 1 |
| Nambiar, S; Schumann, K; Walinsky, S | 1 |
| Biswas, S; Deb, U | 1 |
| Abdel-Rahman, SM; Mirzayev, F; Stancil, SL | 1 |
| Dong, L; Fu, Y; Huang, H; Huo, F; Jing, W; Li, Y; Ma, Y; Pang, Y; Zhao, L; Zong, Z | 1 |
| Gupta, R; Hafkin, J; Hittel, N; Martin, A | 1 |
| Akkerman, O; Alffenaar, JW; Amale, R; Centis, R; D'Ambrosio, L; Ganatra, S; Maryandyshev, A; Migliori, GB; Mullerpattan, J; Pontali, E; Sadutshang, TD; Sotgiu, G; Tiberi, S; Topgyal, S; Udwadia, ZF | 1 |
| Chang, KC; Cox, H; Dheda, K; Esmail, A; Lange, C; Wasserman, S | 1 |
| Barkane, L; Gupta, R; Hittel, N; Kuksa, L | 1 |
| Aarti, C; Barbabosa-Pliego, A; Khusro, A; Salem, AZM | 1 |
| Akkerman, OW; Alffenaar, JW; Bolhuis, MS; de Lange, WCM; de Vries, G; de Zwaan, R; Dedicoat, M; Frijlink, HW; Gajraj, R; Grasmeijer, F; Hagedoorn, P; Kerstjens, HAM; Smith, G; van der Werf, TS; van Soolingen, D | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Spanevello, A; Visca, D | 1 |
| Arbex, MA; D'Ambrosio, L; Dalcolmo, M; Duarte, R; Gaga, M; Migliori, GB; Munoz-Torrico, M; Rendon, A; Silva, DR; Tiberi, S; Visca, D; Zumla, A | 1 |
| Choi, H; Kim, KJ; Lee, SH; Yang, JS | 1 |
| Bamrah Morris, S; Goswami, ND; Khan, AN; Lardizabal, AA | 1 |
| Okumura, M; Yoshiyama, T | 1 |
| Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD | 1 |
| Hoffmann, H; Hofmann-Thiel, S; Kranzer, K; Krieger, D; Merker, M; Niemann, S; Polsfuss, S; Rüssmann, H; Schönfeld, N | 1 |
| Chu, N; Huang, H; Jing, W; Pang, Y; Shang, Y; Wang, F; Wen, S; Xue, Y; Zhang, T; Zong, Z | 1 |
| Alffenaar, JC; Marais, BJ; Sintchenko, V | 1 |
| Bethunaickan, R; Chandramohan, Y; Padmanaban, V; Ranganathan, UD; Swaminathan, S; Tripathy, S | 1 |
| Jeon, D; Jhun, BW; Kang, B; Kang, H; Koh, WJ; Kwak, N; Lee, T; Mok, J; Yim, JJ | 1 |
| Elamin, AA; Singh, M; Stehr, M | 1 |
| Andersson, J; Axelsson-Robertson, R; Keshavjee, S; Lutckii, A; Maeurer, M; Master, I; Parida, SK; Rao, MV; Singh, N; Zumla, A | 1 |
| Blasi, F; Caminero Luna, J; Centis, R; D'Ambrosio, L; Dara, M; Esposito, S; Marais, B; Matteelli, A; Migliori, GB; Schaaf, HS; Tadolini, M | 1 |
| Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW | 1 |
| Borroni, E; Centis, R; Ciconali, G; Cirillo, D; Codecasa, LR; Faccini, M; Ferrarese, M; Gesu, GP; Mazzola, E; Zellweger, JP | 1 |
| Aggarwal, D; Khurana, AK | 1 |
| Gruber, K | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Sotgiu, G | 1 |
| Akkerman, OW; Alffenaar, JW; Daskapan, A; de Lange, WC; Kosterink, JG; Stienstra, Y; van der Werf, TS | 1 |
| Centis, R; Codecasa, LR; Esposito, S | 1 |
| Barry, CE | 1 |
| Cirule, A; Gao, M; Geiter, LJ; Gupta, R; Wells, CD; Xiao, H | 1 |
| Caminero, JA; Scardigli, A | 1 |
| Centis, R; D'Ambrosio, L; Matteelli, A; Migliori, GB; Tadolini, M | 1 |
| Cox, H; Furin, J; Lessem, E; Mason, L; Reed, C; Seaworth, B | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Sotgiu, G; Spanevello, A | 1 |
| Diel, R; Gibbert, J; Wirth, D; Wolfson, LJ | 1 |
| Brigden, G; du Cros, P; Wong, S | 1 |
| Beckert, P; Hoffmann, H; Hofmann-Thiel, S; Jaton, K; Keller, PM; Kohl, TA; Merker, M; Nedialkova, L; Niemann, S; Rothe, T; Sahalchyk, E | 1 |
| Bouvet, E; Fréchet-Jachym, M; Lachâtre, M; Le Dû, D; Rioux, C; Veziris, N; Yazdanpanah, Y | 1 |
| Furin, J; Master, I | 1 |
| Centis, R; D'Ambrosio, L; Enwerem, M; Lingtsang, RD; Migliori, GB; Sadutshang, TD; Tadolini, M; Tiberi, S | 2 |
| Akkerman, OW; Alffenaar, JC; Anthony, RM; Cobelens, FG; Grobusch, MP; Heysell, S; Tiberi, S; Van Soolingen, D | 1 |
| Wallis, RS | 1 |
| Bianchini, S; Bosis, S; Esposito, S; Migliori, GB; Principi, N; Tadolini, M | 1 |
| Centis, R; D'Ambrosio, L; Esposito, S; Migliori, GB; Pontali, E; Sotgiu, G; Tadolini, M; Tiberi, S | 1 |
| Cohen, J | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Muttil, P; Padilla, D; Sung, JC; Telko, M; Verberkmoes, JL | 1 |
| Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS | 1 |
| Cirule, A; Danilovits, M; Geiter, LJ; Kummik, T; Kurve, A; Leimane, V; Levina, K; Manissero, D; Pehme, L; Skenders, G; Skripconoka, V; Tomson, T; Wells, CD | 1 |
| Zhang, Y | 1 |
18 review(s) available for azomycin and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2023 |
Pretomanid: The latest USFDA-approved anti-tuberculosis drug.
Topics: Antitubercular Agents; Drug Approval; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; United States; United States Food and Drug Administration | 2021 |
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
Topics: Antitubercular Agents; Computational Biology; Diarylquinolines; Drug Design; Extensively Drug-Resistant Tuberculosis; Humans; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Peptides; Tuberculosis; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Topics: Adolescent; Antitubercular Agents; Child; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Repositioning; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles | 2018 |
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles | 2019 |
Filling the pipeline - new drugs for an old disease.
Topics: Adamantane; Antitubercular Agents; Cyclic GMP-Dependent Protein Kinases; Diarylquinolines; Enzymes; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Molecular Targeted Therapy; Mycobacterium tuberculosis; Nitroimidazoles; Quantitative Structure-Activity Relationship | 2014 |
Totally drug-resistant tuberculosis and adjunct therapies.
Topics: Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Genotype; Global Health; Host-Pathogen Interactions; Humans; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones | 2015 |
Novel drugs against tuberculosis: a clinician's perspective.
Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Europe; Extensively Drug-Resistant Tuberculosis; Humans; Japan; Mycobacterium tuberculosis; Mycolic Acids; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; World Health Organization | 2015 |
Management of drug resistantTB in patients with HIV co-infection.
Topics: Antitubercular Agents; Coinfection; Diarylquinolines; Disease Management; Extensively Drug-Resistant Tuberculosis; HIV Infections; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.
Topics: Antitubercular Agents; Biomarkers; Clinical Trials as Topic; Coinfection; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; HIV Infections; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Precision Medicine | 2017 |
Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Italy; Male; Nitroimidazoles; Oxazoles | 2016 |
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
2 trial(s) available for azomycin and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Intention to Treat Analysis; Linezolid; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
Delamanid for Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Sputum; Treatment Outcome | 2015 |
47 other study(ies) available for azomycin and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Georgia; Humans; Linezolid; Nitroimidazoles; Philippines; South Africa; Tuberculosis, Multidrug-Resistant | 2021 |
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Granuloma; Humans; Linezolid; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Nitroimidazoles | 2022 |
Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Extensively Drug-Resistant Tuberculosis; Feasibility Studies; Female; Humans; Male; Meropenem; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.
Topics: Antitubercular Agents; Biological Availability; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Lopinavir; Male; Nitroimidazoles; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
Topics: Adolescent; Antitubercular Agents; Child; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Nitroimidazoles; Oxazoles; Sputum; Tomography, X-Ray Computed | 2020 |
An Experience with Delamanid in an XDR TB Case - Case Report.
Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Male; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2021 |
Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Topics: Adolescent; Antitubercular Agents; Child; Cohort Studies; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Nitroimidazoles; Oxazoles; Republic of Belarus | 2021 |
Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18.
Topics: Adult; Antitubercular Agents; Cohort Studies; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Nitroimidazoles; Oxazoles; Republic of Belarus; Treatment Outcome | 2021 |
Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.
Topics: Adolescent; Ambulatory Care Facilities; Antitubercular Agents; Child; Child, Preschool; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; India; Infant; Infant, Newborn; Male; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration | 2021 |
Topics: Antitubercular Agents; Beijing; China; Clofazimine; Diarylquinolines; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2017 |
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Communicable Disease Control; Compassionate Use Trials; Extensively Drug-Resistant Tuberculosis; Female; Global Health; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; World Health Organization | 2017 |
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Nitroimidazoles; Oxazoles; Tuberculosis, Pulmonary; Young Adult | 2017 |
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Extensively Drug-Resistant Tuberculosis; Female; Humans; Latvia; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Colistin; Diarylquinolines; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Male; Medication Adherence; Mycobacterium tuberculosis; Netherlands; Nitroimidazoles; Oxazoles; Patient Isolation; Phenotype; Trimethoprim, Sulfamethoxazole Drug Combination; United Kingdom | 2018 |
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Topics: Antitubercular Agents; Diarylquinolines; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Tuberculosis, Multidrug-Resistant | 2018 |
Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.
Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Compassionate Use Trials; Extensively Drug-Resistant Tuberculosis; Health Services Accessibility; Humans; Nitroimidazoles; Oxazoles; United States | 2018 |
[EXPERIENCE OF USE OF NEW ANTI-TUBERCULOUS DRUG, DELAMANID IN MULTI- AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS CASES IN OUR HOSPITAL].
Topics: Adult; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Oxazoles | 2016 |
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Treatment Outcome | 2019 |
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs.
Topics: Diarylquinolines; Drug Resistance; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles | 2019 |
In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis, Multidrug-Resistant; Xanthenes | 2019 |
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea.
Topics: Adult; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Republic of Korea; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.
Topics: Antitubercular Agents; Child; Compassionate Use Trials; Disease Outbreaks; Europe; Extensively Drug-Resistant Tuberculosis; Humans; Italy; Male; Nitroimidazoles; Oxazoles; Program Development; Societies, Medical; Treatment Outcome; World Health Organization | 2014 |
Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal.
Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Male; Nitroimidazoles; Oxazoles | 2015 |
ERS/WHO Tuberculosis Consilium assistance in extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Male; Nitroimidazoles; Oxazoles | 2015 |
Access sought to tuberculosis drug from nutraceutical company.
Topics: Antitubercular Agents; Compassionate Use Trials; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles | 2015 |
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.
Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Male; Nitroimidazoles; Oxazoles | 2015 |
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.
Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Male; Nitroimidazoles; Oxazoles | 2015 |
Timing is everything for compassionate use of delamanid.
Topics: Antitubercular Agents; Compassionate Use Trials; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles | 2015 |
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Topics: Antitubercular Agents; Carbapenems; Clavulanic Acid; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Infectious Disease Medicine; Linezolid; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Compassionate and optimum use of new tuberculosis drugs.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Health Services Accessibility; Humans; Male; Nitroimidazoles; Oxazoles | 2015 |
Compassionate and optimum use of new tuberculosis drugs.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Health Services Accessibility; Humans; Male; Nitroimidazoles; Oxazoles; Pneumonectomy | 2015 |
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Topics: Antitubercular Agents; Computer Simulation; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Germany; Humans; Markov Chains; Models, Economic; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2015 |
Barriers to new drug development in respiratory disease.
Topics: Antitubercular Agents; Awards and Prizes; Diarylquinolines; Drug Discovery; Extensively Drug-Resistant Tuberculosis; Humans; Motivation; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.
Topics: Adult; Antitubercular Agents; Beijing; Compassionate Use Trials; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genotype; Humans; Male; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Refugees; Tibet | 2016 |
Bedaquiline plus delamanid for XDR tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Health Services Accessibility; Humans; Male; Nitroimidazoles; Oxazoles | 2016 |
Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Health Services Accessibility; Humans; Male; Nitroimidazoles; Oxazoles; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2016 |
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; Nitroimidazoles; Oxazoles | 2016 |
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Easier cure for resistant TB.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Baltimore; Clinical Trials as Topic; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; South Africa; Sputum; Treatment Outcome | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Antitubercular Agents; Chemistry, Pharmaceutical; Colony Count, Microbial; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Guinea Pigs; Humans; Latent Tuberculosis; Lung; Male; Nitroimidazoles; Particle Size; Powders; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2010 |
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors | 2012 |
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2013 |